Immunization with Interleukin-2 Transfected Melanoma Cells. A Phase I–II Study in Patients with Metastatic Melanoma. University Hospital Leiden

Human Gene Therapy

Volumn 4, Issue 3, 1993, Pages 323-330

  Osanto, S ^a   Brouwenstyn N ^a   Vaessen, N ^a   Figdor, C G ^a   Melief, C J M ^a   Schrier, P I ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; RECOMBINANT INTERLEUKIN 2;

ALLOTRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELL TRANSPLANTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; METASTASIS; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROTEIN SECRETION; TREATMENT PLANNING;

CLINICAL PROTOCOLS; GENE THERAPY; HUMAN; IMMUNOTHERAPY; INTERLEUKIN-2; MELANOMA; SKIN NEOPLASMS; TRANSFECTION; TUMOR CELLS, CULTURED; VACCINATION;

EID: 0027304075     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.1993.4.3-323     Document Type: Article

References (33)

1. Wolfel T, E Klehmann, CA Muller, KH Schiitt, KH Meyer zum Buschenfelde and A Knuth. Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification ofhuman histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. J Exp Med 1989; 170: 797-810.
2. Kawakami Y, R Zakut, SL Topalian, H Stotter and SA Rosenberg. Shared human melanoma antigens—Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas. J Immunol 1992; 148: 638-643.
3. Crowley NJ, Slingluff CL, Darrow TL, and Seigler HF. Generation of human autologous melanoma-specific cytotoxic T-cells using HLA-A2-matched allogeneic melanomas. Cancer Res 1990; 50: 492-498.
4. Van der Bruggen P, C Traversari, P Chomez, C Lurquin, EDE Plaen, B Van den Eynde, A Knuth and T Boon. A gene encoding an antigen recognized by cytolytic lymphocytes-T on a human melanoma. Science 1991; 254; 1643-1647.
5. Grimm EA, Mazumder A, Zhang HZ, and Rosenberg SA. The lymphokine-activated killer cell phenomenon: lysis of NK resistant fresh solid tumor cells by IL 2-activated autologous human peripheral blood lymphocytes. J Exp Med 1982; 155: 1823-1841.
6. Philips IH, and Lanier LL. Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med 1986; 164: 814-825.
7. Ortaldo JR, Mason A, and Overton R. Lymphokine-activated killer cells. Analysis of progenitors and effectors. J Exp Med 1986; 164: 1193-1205.
8. Mazumder A, and Rosenberg SA. Successful immunotherapy of NK-resistent established pulmonary melanoma metastases with LAK cells and recombinant IL-2. Science 1984; 225: 1487-1489.
9. Mule JJ, Shu S, Schwarz SL, and Rosenberg SA. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 1984; 225: 1487-1489.
10. Lafreniere R, Rosenberg SA. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer (LAK) cells. Cancer Res 1985; 45: 3735-3741.
11. Rosenberg SA, Lotze MT, Muul LM, et al. Special report: observations on the systemic administration of autologous lymphokineactivated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985; 313: 1485-1492.
12. West WH, Tauer KW, Yanneui JR, et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987; 316: 898-905.
13. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987; 316: 889-897.
14. Rosenstein M, Ettinghausen SE, and Rosenberg SA. Extravasation of intravascular fluid mediated by the systemic administration of recombinant Interleukin 2. J Immunol 1986; 137: 1735-1742.
15. Rosenberg SA, Packard BS. Aebersold PM, et al. Use of tumorinfiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 1988; 319: 1676-1680.
16. Rosenberg SA, Lotze MT, Yang CJ, et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann of Surgery 1989; 210: 474-485.
17. Fearon ER, Itaya T, Hunt B, Vogelstein B and Frost P. Induction in a murine tumor of immunogenic tumor variants by transfection with a foreign gene. Cancer Res 1988; 38: 2975-2980.
18. Bubenik J, J Simova and T Jandlova. Immunotherapy of cancer using local administration of lymphoid cells transformed by IL-2 cDNA and constitutively producing lL-2. Immunol Letters 1990; 23: 287-292.
19. Fearon ER, DM Pardoll. T Itaya, P Golumbek, HI Levitsky, JW Simons, H Karasuyama, B Vogelstein and P Frost, lnterleukin-2 production by tumor cells bypasses T-helper function in the generation of an antitumor response. Cell 1990; 60: 397-403.
20. Gansbacher B, K Zier, B Daniels, K Cronin, R Bannerii and E Gilboa. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protected immunity. J Exp Med 1990; 172: 1217-1224.
21. Tepper RI, PK Pattengale and P Leder. Murine interleukin 4 displays potent anti-tumor activity in vivo. Cell 1991; 57: 503-512.
22. Golumbek PT, AJ Lazenby, HI Levitsky, LM Jaffee, H Karasuyama, M Baker and DM Pardoll. Treatment of established renal cancer by tumor cells engineered to secrete Interleukin-4. Science 1991; 254: 713-716.
23. + T-Cell-dependent tumor rejection. J Exp Med 1991: 174: 1291-1298.
24. Watanabe Y, K Kuribayashi, S Miyatake, K Nishihara, E Nakayama, T Taniyama and T Sakata. Exogenous expression of mouse interferon-T cDNA in mouse C1300 neuroblastoma cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc Natl Acad Sci USA 1989; 86: 9456-9460.
25. Gansbacher B, R Bannerji, B Daniels, K Zier, K Cronin and E Gilboa. Retroviral vector-mediated T-interferon gene transfer into tumor cells generates potent and long lasting anti-tumor immunity. Cancer Res 1990; 50: 7820-7825.
26. Maruguchi Y, KI Toda, K Fujii, S Imamura and Y Watanabe. Survival period of tumor-bearing mice is prolonged after the interferon-gamma-producing gene transfer. Cancer Lett 1990; 60: 41-49.
27. Asher AL, JJ Mule, A Kasid, NP Restifo. JC Salo, CM Reichert, G Jaffe, B Fendley, M Kriegler and SA Rosenberg. Murine tumor cells transduced with the gene for tumor necrosis factor ct. J Immunol 1991; 146: 3227-3234.
28. Blankenstein T, Z Qin, K Uberia, W Muller, H Rosen, H-D Volk and T Diamantstein. Tumor suppression after tumor cell-targeted tumor necrosis factor ct gene transfer. J Exp Med 1991:173:1047.
29. Colombo MP, G Ferrara, A Stoppacciaro, M Parenza, M Rodolfo, F Mavilio and G Parmiani. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med 1991; 173: 889-897.
30. Li W, T Diamantstein and T Blankenstein. Lack of tumorigenicity of Interleukin 4 autocrine growing cells seems related to the antitumor function of Interleukin 4. Mol Immunol 1990; 27: 1331-1337.
31. Blankenstein T, W Li, W Muller and T Diamantstein. Retroviral Interieukin 4 gene transfer into a Interieukin 4-dependent cell line results in autocrine growth but not in tumorigenicity. Eur J Immunol 1990; 20: 935-938.
32. V. Ley, Langlade-Demoyen P, Kourilsky P and Larsson-Sciard E-L. Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes in vivo. Eur J Immunol 1991; 21: 851-854.
33. Rosenberg SA, Aebersold P, Cornetta K, et al. Gene transfer into humans—immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 1990; 323: 570-578.